vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $270.4M, roughly 1.0× Enhabit, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs -14.3%, a 30.9% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 4.7%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $3.3M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 1.5%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
ALAB vs EHAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $270.4M |
| Net Profit | $45.0M | $-38.7M |
| Gross Margin | 75.6% | — |
| Operating Margin | 24.7% | -12.3% |
| Net Margin | 16.6% | -14.3% |
| Revenue YoY | 91.8% | 4.7% |
| Net Profit YoY | 82.0% | 15.9% |
| EPS (diluted) | $0.25 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $270.4M | ||
| Q3 25 | $230.6M | $263.6M | ||
| Q2 25 | $191.9M | $266.1M | ||
| Q1 25 | $159.4M | $259.9M | ||
| Q4 24 | $141.1M | $258.2M | ||
| Q3 24 | $113.1M | $253.6M | ||
| Q2 24 | $76.8M | $260.6M | ||
| Q1 24 | $65.3M | $262.4M |
| Q4 25 | $45.0M | $-38.7M | ||
| Q3 25 | $91.1M | $11.1M | ||
| Q2 25 | $51.2M | $5.2M | ||
| Q1 25 | $31.8M | $17.8M | ||
| Q4 24 | $24.7M | $-46.0M | ||
| Q3 24 | $-7.6M | $-110.2M | ||
| Q2 24 | $-7.5M | $-200.0K | ||
| Q1 24 | $-93.0M | $200.0K |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 76.2% | — | ||
| Q2 25 | 75.8% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 77.7% | — | ||
| Q2 24 | 77.9% | — | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | -12.3% | ||
| Q3 25 | 24.0% | 6.4% | ||
| Q2 25 | 20.7% | 6.3% | ||
| Q1 25 | 7.1% | 6.1% | ||
| Q4 24 | 0.1% | -16.0% | ||
| Q3 24 | -7.9% | -38.6% | ||
| Q2 24 | -31.7% | 4.3% | ||
| Q1 24 | -127.1% | 4.9% |
| Q4 25 | 16.6% | -14.3% | ||
| Q3 25 | 39.5% | 4.2% | ||
| Q2 25 | 26.7% | 2.0% | ||
| Q1 25 | 20.0% | 6.8% | ||
| Q4 24 | 17.5% | -17.8% | ||
| Q3 24 | -6.7% | -43.5% | ||
| Q2 24 | -9.8% | -0.1% | ||
| Q1 24 | -142.5% | 0.1% |
| Q4 25 | $0.25 | $-0.76 | ||
| Q3 25 | $0.50 | $0.22 | ||
| Q2 25 | $0.29 | $0.10 | ||
| Q1 25 | $0.18 | $0.35 | ||
| Q4 24 | $1.23 | $-0.92 | ||
| Q3 24 | $-0.05 | $-2.20 | ||
| Q2 24 | $-0.05 | $0.00 | ||
| Q1 24 | $-1.77 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $43.6M |
| Total DebtLower is stronger | — | $426.0M |
| Stockholders' EquityBook value | $1.4B | $534.0M |
| Total Assets | $1.5B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $43.6M | ||
| Q3 25 | $140.4M | $56.9M | ||
| Q2 25 | $162.3M | $37.1M | ||
| Q1 25 | $86.4M | $39.5M | ||
| Q4 24 | $79.6M | $28.4M | ||
| Q3 24 | $126.1M | $45.7M | ||
| Q2 24 | $421.1M | $28.5M | ||
| Q1 24 | $696.1M | $36.5M |
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $441.5M | ||
| Q2 25 | — | $456.9M | ||
| Q1 25 | — | $467.3M | ||
| Q4 24 | — | $492.6M | ||
| Q3 24 | — | $502.9M | ||
| Q2 24 | — | $512.7M | ||
| Q1 24 | — | $526.7M |
| Q4 25 | $1.4B | $534.0M | ||
| Q3 25 | $1.3B | $566.8M | ||
| Q2 25 | $1.1B | $552.4M | ||
| Q1 25 | $1.0B | $543.2M | ||
| Q4 24 | $964.8M | $523.5M | ||
| Q3 24 | $889.6M | $566.1M | ||
| Q2 24 | $845.3M | $674.3M | ||
| Q1 24 | $808.8M | $672.3M |
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $983.1M | $1.3B | ||
| Q2 24 | $915.5M | $1.4B | ||
| Q1 24 | $864.9M | $1.4B |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $4.4M |
| Free Cash FlowOCF − Capex | $76.6M | $3.3M |
| FCF MarginFCF / Revenue | 28.3% | 1.2% |
| Capex IntensityCapex / Revenue | 6.9% | 0.4% |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $4.4M | ||
| Q3 25 | $78.2M | $37.8M | ||
| Q2 25 | $135.4M | $10.6M | ||
| Q1 25 | $10.5M | $17.9M | ||
| Q4 24 | $39.7M | $-4.1M | ||
| Q3 24 | $63.5M | $28.4M | ||
| Q2 24 | $29.8M | $9.6M | ||
| Q1 24 | $3.7M | $17.3M |
| Q4 25 | $76.6M | $3.3M | ||
| Q3 25 | $65.9M | $36.2M | ||
| Q2 25 | $133.3M | $8.7M | ||
| Q1 25 | $6.0M | $17.6M | ||
| Q4 24 | $24.3M | $-4.7M | ||
| Q3 24 | $46.8M | $27.7M | ||
| Q2 24 | $28.5M | $8.9M | ||
| Q1 24 | $228.0K | $15.5M |
| Q4 25 | 28.3% | 1.2% | ||
| Q3 25 | 28.6% | 13.7% | ||
| Q2 25 | 69.5% | 3.3% | ||
| Q1 25 | 3.7% | 6.8% | ||
| Q4 24 | 17.2% | -1.8% | ||
| Q3 24 | 41.4% | 10.9% | ||
| Q2 24 | 37.1% | 3.4% | ||
| Q1 24 | 0.3% | 5.9% |
| Q4 25 | 6.9% | 0.4% | ||
| Q3 25 | 5.3% | 0.6% | ||
| Q2 25 | 1.1% | 0.7% | ||
| Q1 25 | 2.8% | 0.1% | ||
| Q4 24 | 10.9% | 0.2% | ||
| Q3 24 | 14.8% | 0.3% | ||
| Q2 24 | 1.7% | 0.3% | ||
| Q1 24 | 5.2% | 0.7% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | 3.41× | ||
| Q2 25 | 2.64× | 2.04× | ||
| Q1 25 | 0.33× | 1.01× | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 86.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
